Canopy Growth (CGC)
(Delayed Data from NSDQ)
$6.21 USD
+0.07 (1.14%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $6.20 -0.01 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.21 USD
+0.07 (1.14%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $6.20 -0.01 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Zacks News
5 Best Leveraged ETFs of Last Week Up At Least 10%
by Sanghamitra Saha
Wall Street was mixed-to-downbeat last week. A new 40-year high inflation reading and rising rate worries played spoilsport.
Canopy Growth Corporation (CGC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of 4.35% and 1.12%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Canopy Growth (CGC) in Q3 Earnings?
by Zacks Equity Research
New product launches across the CBD product portfolio and robust demand for legal cannabis products are likely to drive Canopy Growth's (CGC) Q3 top line.
Will Canopy Growth Corporation (CGC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Canopy Growth Corporation (CGC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $7.40, marking a +1.51% move from the previous day.
Canopy Growth Corporation (CGC) Stock Moves -1.05%: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $7.56 in the latest trading session, marking a -1.05% move from the prior day.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $8.40, marking a -0.12% move from the previous day.
Canopy Growth Corporation (CGC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $8.21, moving -1.91% from the previous trading session.
Ulta Beauty and Freshpet have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Ulta Beauty and Freshpet have been highlighted as Zacks Bull and Bear of the Day
Ride The Cannabis Legalization Wave With These 3 Stocks
by Tirthankar Chakraborty
Stocks like Cronos Group (CRON), Canopy Growth (CGC) and Innovative Industrial Properties (IIPR) are sure to benefit at present amid the cannabis legalization wave.
Do Options Traders Know Something About Canopy Growth (CGC) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to for Canopy Growth (CGC) stock based on the movements in the options market lately.
Canopy Growth Corporation (CGC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $9.27 in the latest trading session, marking a +1.31% move from the prior day.
Should You Buy Beaten Down Cannabis Stocks & ETFs Now?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.
Canopy Growth Corporation (CGC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -178.57% and -6.23%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Canopy Growth (CGC) in Q2 Earnings?
by Zacks Equity Research
Canopy Growth's (CGC) newly-added Ace Valley and Supreme Cannabis hold part of the company's market share in fiscal Q2.
Clover Health (CLOV) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Clover Health's (CLOV) third-quarter results are likely to benefit from Direct Contracting and strategic partnerships.
Canopy Growth Corporation (CGC) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Canopy Growth Corporation (CGC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Humana (HUM) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Humana's (HUM) third-quarter earnings are expected to have gained from higher revenues and a solid contribution from its Retail and Healthcare Services segments.
Canopy Growth Corporation (CGC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $13.01, marking a +1.76% move from the previous day.
4 Medical Products Stocks Poised to Beat This Earnings Season
by Urmimala Biswas
Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.
AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.
DENTSPLY SIRONA (XRAY) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) third-quarter results are likely to reflect strong segmental performance.
Conformis (CFMS) to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Conformis' (CFMS) third-quarter results are likely to reflect strength in core products.
PerkinElmer (PKI) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results are likely to reflect strong performance at the Diagnostics segment.
McKesson (MCK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal second-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.